- Article
Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
- Keisuke Enomoto,
- Shun Hirayama,
- Naoko Kumashiro,
- Xuefeng Jing,
- Takahito Kimura,
- Shunji Tamagawa,
- Ibu Matsuzaki,
- Shin-Ichi Murata and
- Muneki Hotomi
E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer. However, a majority of patients do not continue lenvatinib intake...